The CNS drug market presents significant profit opportunities, but also carries high risks for companies aiming to achieve blockbuster status. Pipelines based on novel molecular targets to treat underlying disease promise to transform the treatment of psychiatric and neurological diseases, however research and development of these drugs requires an innovative approach to ensure investment is maximized.

Innovations in CNS: Novel therapeutics and future R&D strategies assesses novel treatments in development for major CNS disorders, comparing them with existing medications in terms of unmet need and forecasting their success in the commercial market. This report will enable you to understand the research tactics of your competitors and develop winning strategies for future growth in the lucrative CNS market. The report provides a survey of the pipelines of all of the major players in the CNS area. Detailed company profiles featured in the report include: AstraZeneca, GlaxoSmithKline, Merck & Co, Pfizer, and Sanofi-Aventis.

Use this report to understand the factors that will ensure your product pipeline achieves clinical and commercial success and analyze the product pipelines of the leading companies in the CNS market.

Key findings of the report...

• CNS pipelines show an unprecedented level of novelty against the
industry trend of fewer new mechanisms making it to the market.
• Early signs of the long awaited impact of molecular biological
technology in the CNS area are positive, with antibodies for
Alzheimer’s disease beginning to make real progress.
• Companies are moving away from merely treating symptoms to
looking for interventions that treat the underlying disease state for
conditions such as Alzheimer’s and Parkinson’s diseases.
• In spite of some early failures companies are still investing
enormous resources in bringing NK-1 (Substance P) antagonists
through clinical development.
• The success of antagonists for NK-2 or NK-3 receptors for the
treatment of psychoses is likely to open up intense activity in that area
as companies strive to catch up with the current leaders.
• Company size does not relate to level of novelty in pipelines. Large
companies vary hugely in the level of innovation in their pipelines and
small companies can compete in the blockbuster arena with innovative
molecules.

Key questions answered in this report

• What indications will see an increase in innovative launches in the
next few years?
• Which companies will become key players in the CNS market?
• What roles will big pharma and SME/biotech companies play in the
future of CNS treatment?
• Is molecular biology only an enabling technology in CNS drug
discovery?
• What does the future of hold for CNS blockbuster drugs?
• Which pipeline products feature highest growth potential and why?
• What are the key unmet needs within the major sub-indications of
depression, anxiety, schizophrenia, sleep disorders, Alzheimer’s,
movement disorders and pain?

Top five reasons to order your copy today

• Analyze patient potential, economic burden and key unmet needs in
10 major CNS disorders across the US, EU and Japan, including
schizophrenia, depression and Alzheimer’s disease.
• Understand how key preclinical and clinical trials are impacting
CNS drug development, enabling you to assess new innovations and
anticipate future trends in the market.
• Assess your organisation’s position in the market-place, and develop
innovative future strategies to ensure you are positioned for
success.
• Discover novel treatment strategies for all major therapeutic areas in
psychaitry and neurology.
• Gain access to the CNS pipelines of leading companies including
Sanofi-Aventis, Pfizer and AstraZeneca to understand their differing
portfolio management strategies.